代谢与心血管疾病论坛-4

Metabolic & CVD Forum-4

11/22 13:30-15:30

403 (403)

主持

谢小洁(XIE Xiao-Jie) (浙江大学医学院附属第二医院), 张岩(ZHANG Yan) (北京大学医学部心血管研究所), 王胜煌(WANG Sheng-Huang) (宁波大学附属第一医院)
13:30- 15:30

讨论嘉宾

John R. Nelson (California Cardiovascular Institute and Lipid Clinic in Fresno, California), 李建平(LI Jian-Ping) (北京大学第一医院), 阮雄中(RUAN Xiong-Zhong) (重庆医科大学脂质中心), 李建军(LI Jian-Jun) (中国医学科学院阜外医院)
14:20-14:40

降脂新药研究进展

Research Progress of New Lipid-Lowering Drugs

李建平(LI Jian-Ping) (北京大学第一医院)
14:40-15:00

代谢共病的脂代谢特点与临床对策

Lipid Metabolism Characteristics and Clinical Countermeasures of Metabolic Comorbidities

阮雄中(RUAN Xiong-Zhong) (重庆医科大学脂质中心)
15:00-15:20

VAP技术检测血脂与脂蛋白亚组分及其临床应用中国专家共识（2025版）解读

Interpretation of the Chinese Expert Consensus on the Detection of Blood Lipids and Lipoprotein Subfractions by VAP Technology and Their Clinical Application (2025 Edition)

鄢盛恺(YAN Sheng-Kai) (遵义医科大学)
13:30-13:35

致辞

Opening Remarks

王建安(WANG Jian-An) (浙江大学医学院附属第二医院)
14:00-14:20

降低高甘油三酯血症患者的残余心血管风险：二十碳五烯酸的独特作用

Reducing Residual Cardiovascular Risk in Patients with Hypertriglyceridemia: the Unique Role of Eicosapentaenoic acid

John R. Nelson (California Cardiovascular Institute and Lipid Clinic in Fresno, California)
15:20-15:30

总结

Summary
13:35-14:00

中外论道：聚焦国内外最新血脂前沿 1、ASCVD剩留风险的现状和研究进展 2、剩留风险的评估指标 3、剩留风险的靶点和新药研究

Sino-Foreign Dialogue: Focus on the Latest Domestic and International Lipid Frontiers 1. Current Status and Research Progress of ASCVD Residual Risk 2. Evaluation Indicators of Residual Risk 3. Targets and New Drug Research for Residual Risk

打印